» Articles » PMID: 39455556

The Oncogenic Axis YAP/MYC/EZH2 Impairs PTEN Tumor Suppression Activity Enhancing Lung Tumorigenicity

Overview
Date 2024 Oct 25
PMID 39455556
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor suppressor PTEN (phosphatase and tensin homolog deleted in chromosome 10) is genetically deleted or downregulated in many cancer types. Loss of PTEN protein expression is frequently found in lung cancer while genetic alterations are less abundant. PTEN expression is regulated at multiple genetic and epigenetic levels and even partial reduction of its expression increases cancer occurrence. We show that YAP and TAZ cooperate with EZH2, and MYC to transcriptionally repress onco-suppressor genes, including PTEN, in non-small cell lung cancer (NSCLC) cells. YAP/TAZ-EZH2-MYC transcriptional regulators form a nuclear complex that represses PTEN transcription, while their combinatorial targeting restores PTEN expression, attenuates NSCLC cell growth, and prevents compensatory responses induced by single treatments. Datasets analysis of NSCLC patients revealed that PTEN expression is negatively correlated to YAP/TAZ, EZH2 and MYC and that low expression of PTEN is predictive of poor prognosis, especially at earlier stages of the disease. These findings highlight the repressive role of the YAP/TAZ-EZH2-MYC axis on tumor-suppressor genes and offer a potential therapeutic strategy for lung cancer patients with low PTEN levels.

Citing Articles

Highlighting recent achievements to advance more effective cancer immunotherapy.

Belmonte B, Spada S, Allavena P, Benelli M, Bronte V, Casorati G J Exp Clin Cancer Res. 2025; 44(1):57.

PMID: 39966867 PMC: 11834592. DOI: 10.1186/s13046-025-03316-8.


The correlation between miR-21 single nucleotide polymorphisms and the susceptibility of non-small cell lung cancer.

Zhang M, Zhang M, Han R, Yu X, Song Z J Cardiothorac Surg. 2025; 20(1):76.

PMID: 39833839 PMC: 11748343. DOI: 10.1186/s13019-024-03322-5.

References
1.
Shreberk-Shaked M, Dassa B, Sinha S, Di Agostino S, Azuri I, Mukherjee S . A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer. Cancer Res. 2020; 80(19):4145-4157. PMC: 8916161. DOI: 10.1158/0008-5472.CAN-20-0125. View

2.
Ferrara M, Martini M, DArgento E, Forcella C, Vita E, Di Noia V . PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. Clin Lung Cancer. 2021; 22(4):351-360. DOI: 10.1016/j.cllc.2020.12.008. View

3.
Leiter A, Veluswamy R, Wisnivesky J . The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023; 20(9):624-639. DOI: 10.1038/s41571-023-00798-3. View

4.
Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P . Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions. Biomed Pharmacother. 2023; 158:114204. DOI: 10.1016/j.biopha.2022.114204. View

5.
Gertz J, Savic D, Varley K, Partridge E, Safi A, Jain P . Distinct properties of cell-type-specific and shared transcription factor binding sites. Mol Cell. 2013; 52(1):25-36. PMC: 3811135. DOI: 10.1016/j.molcel.2013.08.037. View